Savara Inc. (NASDAQ:SVRA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Savara Inc. (NASDAQ:SVRA) have been given an average recommendation of “Moderate Buy” by the eight brokerages that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $10.1429.

A number of research firms have weighed in on SVRA. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research note on Tuesday, April 21st. Oppenheimer began coverage on Savara in a research note on Friday, April 24th. They set an “outperform” rating and a $11.00 price objective on the stock. William Blair set a $10.00 price objective on Savara in a research note on Monday, March 16th. HC Wainwright reissued a “buy” rating on shares of Savara in a research note on Monday, March 16th. Finally, Wall Street Zen raised Savara from a “sell” rating to a “hold” rating in a research note on Saturday.

Institutional Investors Weigh In On Savara

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Seven Fleet Capital Management LP raised its position in Savara by 371.1% in the first quarter. Seven Fleet Capital Management LP now owns 295,688 shares of the company’s stock valued at $1,614,000 after purchasing an additional 232,926 shares during the period. Avidity Partners Management LP purchased a new stake in Savara in the first quarter valued at $262,000. Glenmede Trust Co. NA purchased a new stake in Savara in the first quarter valued at $575,000. Bank of America Corp DE raised its position in Savara by 38.9% in the first quarter. Bank of America Corp DE now owns 588,199 shares of the company’s stock valued at $3,212,000 after purchasing an additional 164,603 shares during the period. Finally, Janus Henderson Group PLC purchased a new stake in Savara in the first quarter valued at $247,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Stock Performance

NASDAQ SVRA opened at $5.30 on Wednesday. The stock’s fifty day moving average is $5.28 and its two-hundred day moving average is $5.60. The firm has a market capitalization of $1.09 billion, a P/E ratio of -9.46 and a beta of 0.26. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.47 and a current ratio of 13.47. Savara has a fifty-two week low of $1.98 and a fifty-two week high of $7.01.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). On average, research analysts anticipate that Savara will post -0.57 earnings per share for the current year.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.